New combo therapy shows promise for rare gut tumors
NCT ID NCT05724108
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 52 times
Summary
This phase II trial tests whether adding a drug called triapine to standard radioactive therapy (lutetium Lu 177 dotatate) can better shrink or slow metastatic neuroendocrine tumors. About 94 patients with well-differentiated, somatostatin receptor-positive tumors will be randomly assigned to receive the combo or standard therapy alone. The study aims to see if the combination improves response rates and delays tumor progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180, United States
-
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146, United States
-
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442, United States
-
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, 33176, United States
-
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324, United States
-
UT MD Anderson - League City
League City, Texas, 77573, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Triapine and Lutetium Lu 177 Dotatate
What this could lead to
If it works, this could lead to a more effective treatment for metastatic neuroendocrine tumors, helping shrink or slow tumor growth better than current standard therapy.
What could go wrong
This is a phase II trial with only 94 participants, so results are preliminary. The combination may not prove more effective than standard therapy, and side effects from adding triapine are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.